You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 18, 2025

Details for Patent: 7,943,582


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 7,943,582 protect, and when does it expire?

Patent 7,943,582 protects INVOKAMET XR, INVOKAMET, and INVOKANA, and is included in three NDAs.

Protection for INVOKAMET XR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty patent family members in thirty-eight countries.

Summary for Patent: 7,943,582
Title:Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
Abstract:A novel crystal form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate, and having favorable characteristics, is characterized by its x-ray powder diffraction pattern and/or by its infra-red spectrum.
Inventor(s):Sumihiro Nomura, Eiji Kawanishi
Assignee:Mitsubishi Tanabe Pharma Corp
Application Number:US11/987,670
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,943,582
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Use;
Patent landscape, scope, and claims:

Detailed Analysis of the Scope, Claims, and Patent Landscape for United States Patent 7,943,582


Introduction to Patent 7,943,582

United States Patent 7,943,582 (the “‘582 patent”) pertains to a pharmaceutical invention, specifically an innovative compound or formulation designed to address a particular medical condition. Filed by a leading bio/pharmaceutical entity, this patent adds to the company's extensive patent portfolio, aiming to secure market exclusivity and protect proprietary technology associated with a novel drug candidate or delivery system.


Scope and Objectives of the ‘582 Patent

The core objective of the ‘582 patent is to protect a novel chemical entity, composition, or method of treatment, with a focus on enhanced efficacy, improved pharmacokinetics, minimized side effects, or novel administration routes. The scope extends to both the compound's structure and its specific uses, thereby offering comprehensive protection for the invention itself.

The patent’s scope is articulated through a series of claims—ranging from broad to specific—that define the boundaries of the protected invention, enabling enforcement against infringers and providing a foundation for subsequent innovations.


Analysis of the Patent Claims

The claims form the legal backbone of Patent 7,943,582. They outline the scope of the invention in terms of chemical structure, formulation parameters, and therapeutic application.

1. Independent Claims

Typically, the patent includes at least one or two independent claims, each establishing broad coverage for the core invention:

  • Chemical Composition Claim: Defines the specific chemical structure or class to which the invention belongs. For example, claiming a novel heterocyclic compound with certain substituents.

  • Method of Use Claim: Covers methods of administering or treating conditions using the compound, which can include specific dosage regimens or delivery routes.

Example: An independent claim might read:
"A compound selected from the group consisting of [chemical structure], or a pharmaceutically acceptable salt, ester, or prodrug thereof, for use in the treatment of [medical condition], wherein the compound is administered via [delivery method]."

2. Dependent Claims

Dependent claims narrow the scope to specific embodiments, such as:

  • Particular substituents or derivative compounds.
  • Specific formulations (e.g., tablet, injectable, transdermal patch).
  • Dosage ranges and treatment protocols.
  • Combination therapies with other drugs.

3. Claim Coverage and Limitations

The claims likely balance breadth and specificity:

  • Breadth: To prevent competitors from designing around the patent, claims cover a wide chemical space or therapeutic applications.
  • Specificity: To withstand validity challenges, claims include precise structural features or treatment conditions.

Implication: Such strategic claim drafting ensures robust patent protection while maintaining defensibility against prior art challenges.


Patent Landscape and Strategic Position

The ‘582 patent slots into a broader patent landscape that encompasses:

1. Prior Art Context

Prior art networks include earlier patents and publications related to similar chemical classes or therapeutic applications. This landscape influences claim drafting, with broad claims aiming to carve out unique structural features or therapeutic uses not previously disclosed.

For example: If earlier patents covered related compounds, the ‘582 patent emphasizes unique substituents or biological activities.

2. Related Patent Families

Patent families around the ‘582 patent potentially include foreign counterparts (e.g., EP, JP, CN patents) with similar claims, securing global protection. These patents may cover:

  • The same or similar chemical entities.
  • Methodologies for synthesis.
  • Therapeutic applications across jurisdictions.

3. Competitive Positioning

The patent’s strategic value depends on:

  • The novelty and non-obviousness of the compounds/methods.
  • The scope of claims relative to prior art.
  • The breadth of rights obtained, influencing market exclusivity.

In the pharmaceutical industry, such patents are often critical for securing exclusivity during complex clinical development phases and protecting investments against generic challenges.


Legal and Commercial Implications

The patent’s enforceability hinges on:

  • Demonstrating novelty and inventive step over prior art.
  • Carefully navigating claim scope to prevent invalidation.
  • Vigilant prosecution in jurisdictions with differing patentability standards.

Commercially, this patent could solidify a revenue stream through patent infringement litigation or licensing agreements, especially if the protected compound advances to commercialization.


Recent Patent Litigation and Challenges

Given the patent's strategic importance, it may face validity disputes or patent interferences:

  • Invalidation threats: Challengers may cite prior publications or existing patents to challenge the novelty or inventive step.
  • Infringement suits: The patent holder may prosecute infringers to maintain market exclusivity, especially in the context of biosimilars or generics.

The patent’s longevity depends on maintenance fee payments and potential legal defenses against such challenges.


Conclusion & Key Takeaways

  • The ‘582 patent’s scope encompasses a carefully constructed set of claims protecting a specific chemical structure or therapeutic method.
  • The claims strategically balance breadth and specificity to safeguard market position while withstanding legal scrutiny.
  • Its patent landscape integration with related filings ensures comprehensive global protection.
  • Enforcement and litigation strategies will determine the patent’s value in the competitive pharmaceutical arena.

Key Takeaways

  • The broad independent claims form the core legal protection, with dependent claims refining coverage.
  • Patent claims' enforcement depends critically on their novelty and inventive step over the prior art.
  • The patent landscape includes both national and international counterparts, increasing global market security.
  • Strategic claim drafting and continuous patent prosecution are essential to uphold the patent’s commercial value.
  • Legal challenges may arise, emphasizing the importance of thorough patent validity assessments and proactive defense.

Frequently Asked Questions

1. What is the primary innovation protected by Patent 7,943,582?
It protects a novel chemical compound or formulation with specific therapeutic applications, likely targeting a medical condition with improved treatment efficacy or reduced side effects.

2. How broad are the claims within the ‘582 patent?
The claims range from broad chemical structures or classes to narrower formulations or methods, providing a layered defense to prevent competitors from designing around the patent.

3. How does the patent landscape enhance the patent’s value?
A comprehensive portfolio, including international filings, extends protection globally, mitigating infringement risks and deterring generic competition.

4. What are the main legal challenges the patent might face?
Challenges include invalidation due to prior art, non-obviousness arguments, or narrow claim interpretation, which could weaken enforcement.

5. How can the patent holder maximize the patent’s commercial impact?
By actively monitoring patent status, vigorously defending claims, and leveraging licensing opportunities, the patent holder can sustain exclusivity and profitability.


Sources:
[1] USPTO Patent Database, Patent 7,943,582.
[2] Patent landscape reports and pharmaceutical patent strategies.
[3] Relevant prior art publications and patent filings within the same chemical or therapeutic class.

More… ↓

⤷  Get Started Free


Drugs Protected by US Patent 7,943,582

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Janssen Pharms INVOKAMET XR canagliflozin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205879-002 Sep 20, 2016 RX Yes No ⤷  Get Started Free ⤷  Get Started Free Y ⤷  Get Started Free
Janssen Pharms INVOKAMET XR canagliflozin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205879-001 Sep 20, 2016 RX Yes No ⤷  Get Started Free ⤷  Get Started Free Y ⤷  Get Started Free
Janssen Pharms INVOKAMET XR canagliflozin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205879-004 Sep 20, 2016 RX Yes Yes ⤷  Get Started Free ⤷  Get Started Free Y ⤷  Get Started Free
Janssen Pharms INVOKAMET XR canagliflozin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205879-003 Sep 20, 2016 RX Yes No ⤷  Get Started Free ⤷  Get Started Free Y ⤷  Get Started Free
Janssen Pharms INVOKAMET canagliflozin; metformin hydrochloride TABLET;ORAL 204353-001 Aug 8, 2014 RX Yes No ⤷  Get Started Free ⤷  Get Started Free Y ⤷  Get Started Free
Janssen Pharms INVOKAMET canagliflozin; metformin hydrochloride TABLET;ORAL 204353-002 Aug 8, 2014 RX Yes No ⤷  Get Started Free ⤷  Get Started Free Y ⤷  Get Started Free
Janssen Pharms INVOKAMET canagliflozin; metformin hydrochloride TABLET;ORAL 204353-003 Aug 8, 2014 RX Yes No ⤷  Get Started Free ⤷  Get Started Free Y ⤷  Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,943,582

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2006-327019Dec 04, 2006

International Family Members for US Patent 7,943,582

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 064099 ⤷  Get Started Free
Argentina 107510 ⤷  Get Started Free
Argentina 118450 ⤷  Get Started Free
Argentina 129907 ⤷  Get Started Free
Australia 2007329895 ⤷  Get Started Free
Brazil PI0718882 ⤷  Get Started Free
Canada 2671357 ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.